David Happel is the President and CEO of Cognoa, the leading digital diagnostics and therapeutics company developing FDA cleared pediatric behavioral health solutions. Prior to joining Cognoa, Happel served as President, CEO, and Director at Chrono Therapeutics, a biopharmaceutical company focused on the development of treatments for neurologically debilitating conditions. He also previously served in senior management roles at Horizon Therapeutics, Raptor Pharma, Allergen Research Corporation and others. With 25 years’ industry experience, Happel has an extensive track record of improving clinical and commercial outcomes for cutting-edge health-tech companies.
Researchers and advocates have convincingly shown that the wide gap in diagnoses between boys and girls isn’t simply a matter of boys being significantly more likely to be on the autism spectrum.